IP Library Granted Patent US 9,949,877
Granted Patent B2
US 9,949,877 · App. 14/872,248 · Granted Apr 24, 2018

Photodynamic therapy laser

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,949,877
App. No.
14/872,248
Granted
Apr 24, 2018
Kind
B2
Abstract

A laser system including: a laser source operable to emit a first laser beam having a first operating wavelength and a second laser beam having a second operating wavelength; a fiber optic cable to guide and homogenize the first and second laser beams; an expander to increase the diameter of the first and second laser beams; a cylinder to guide the first and second laser beams and limit respective diameters of the first and second laser beams, wherein the cylinder is positioned after the expander on an optical path of the laser beam; a first optical system to collimate the first and second laser beams, wherein the optical system is positioned after the cylinder on the optical path of the first and second laser beams; a spot-size selector comprising a plurality of apertures, wherein the spot-size selector is positioned after the first optical system on the optical path of the first and second laser beams; and a second optical system to focus the first and second laser beams on a tissue of the patient.

Claims (20)

1. A laser system configured for administering therapy to a patient comprising:

a laser source operable to emit a first laser beam operating a first wavelength and a second laser beam operating a second wavelength, wherein the laser source operates at 1.5 watts or less;

a passive cooling system, wherein the passive cooling system comprises a heat pipe, a heat sink, and a fin array;

a fiber optic cable coupled to the laser source and configured to guide and homogenize the first and second laser beams;

a first optical system coupled to the fiber optic cable and configured to increase the diameter of and collimate the first and second laser beams;

a spot-size selector coupled to the first optical system and comprising a plurality of apertures; and

a second optical system coupled to the spot-size selector and configured to focus the first and second laser beams on an eye tissue of the patient.

2. The laser system of claim 1 , further comprising an optical filter configured to partially reflect the first and second laser beams, wherein the optical filter reflects a first percentage of the first laser beam and a second percentage of the second laser beam, the first percentage being greater than the second percentage.

3. The laser system of claim 2 , wherein the laser system is contained within a single housing.

4. The laser system of claim 3 , wherein the housing is configured to be attached to a slit-lamp microscope.

5. The laser system of claim 1 , wherein the fiber optic cable has a diameter of approximately 350 to 450 microns and a length of approximately 200 to 300 millimeters.

6. A method of activating a photoactive drug administered to a patient intravenously using a laser system according to claim 1 , comprising:

activating the photoactive agent with the first laser beam generated by the laser source, the first laser beam having a first wavelength;

generating the second laser beam operating at a second wavelength, wherein the combined power levels of both the first and second laser beams are 1.5 watts or less;

passively cooling the laser source by coupling the heat sink to the laser source;

guiding the first and second laser beams through the fiber optic cable coupled to the laser source, wherein the fiber optic cable homogenizes the first and second laser beams;

increasing the diameter of and collimating the first and second laser beams;

adjusting a spot-size of the first and second laser beams; and

focusing the first and second laser beams on an eye tissue of the patient; wherein at least the first laser beam activates the photoactive drug within the patient's eye tissue to provide therapy to the patient.

7. The method of claim 6 , wherein the photoactive drug comprises verteporfin.

Assignments (19)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (065709/0253) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072460/0691 →
PATENT SECURITY AGREEMENT Recorded Jul 1, 2025
From: BAUSCH & LOMB INCORPORATED; ALDEN OPTICAL LABORATORIES, INC.; BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 071773/0871 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 049672/0652) Recorded Apr 17, 2024
From: THE BANK OF NEW YORK MELLON
To: BAUSCH + LOMB IRELAND LIMITED; BAUSCH + LOMB CORPORATION
Reel/Frame 067131/0618 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 039380/0385) Recorded Apr 17, 2024
From: BARCLAYS BANK PLC
To: BAUSCH + LOMB IRELAND LIMITED; BAUSCH + LOMB CORPORATION
Reel/Frame 067131/0578 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Apr 17, 2024
From: BARCLAYS BANK PLC
To: BAUSCH + LOMB IRELAND LIMITED; BAUSCH + LOMB CORPORATION
Reel/Frame 067131/0587 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Apr 17, 2024
From: THE BANK OF NEW YORK MELLON
To: BAUSCH + LOMB IRELAND LIMITED; BAUSCH + LOMB CORPORATION
Reel/Frame 067131/0596 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 057821/0800) Recorded Apr 17, 2024
From: THE BANK OF NEW YORK MELLON
To: BAUSCH + LOMB IRELAND LIMITED; BAUSCH + LOMB CORPORATION
Reel/Frame 067131/0651 →
SECURITY INTEREST Recorded Feb 12, 2024
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 066552/0041 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 29, 2023
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 065709/0253 →
CHANGE OF NAME Recorded Jan 13, 2023
From: VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
To: BAUSCH HEALTH COMPANIES INC.
Reel/Frame 062389/0306 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2023
From: BAUSCH HEALTH COMPANIES INC.
To: BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 062375/0428 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043045/0959 →